<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23548">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128113</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1309</org_study_id>
    <nct_id>NCT02128113</nct_id>
  </id_info>
  <brief_title>RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the efficacy and safety of two concentrations of RTA 408 ophthalmic
      suspension for the prevention of corneal endothelial cell loss following cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many ocular diseases are characterized by oxidative stress and/or inflammation.  Oxidative
      stress is also known to adversely impact corneal endothelial cells, and may be a factor
      resulting in the acute decrease in corneal endothelial cell density following ocular
      surgery. While corticosteroids provide potent anti-inflammatory efficacy in a wide range of
      acute and chronic inflammatory ocular diseases, their use is limited by their side effect
      profile, which includes the potential to elevate IOP and induce cataract formation. In
      addition, most available ophthalmic anti-inflammatory treatments, including corticosteroids,
      do not directly protect against the underlying oxidative stress component of the disease
      process. Consequently, there is a clinical need for agents that protect against oxidative
      stress and provide anti-inflammatory efficacy without inducing steroid-like side effects.

      This study will assess the safety and efficacy of RTA 408 Ophthalmic Suspension (0.5% or 1%)
      versus vehicle for the prevention of corneal endothelial cell loss in patients undergoing
      cataract surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Count of corneal endothelial cells</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Count of corneal endothelial cells 12 weeks post cataract surgery, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of inflammation</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine number of patients who have no inflammation 2 weeks post cataract surgery according to the Standardization of Uveitis Nomenclature (SUN) Working Group Inflammatory Scoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of pain</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine number of patients who have no pain 1 day post cataract surgery according to the National Institutes of Health (NIH) Numeric Pain Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Corneal Endothelial Cell Loss</condition>
  <condition>Ocular Pain</condition>
  <condition>Ocular Inflammation</condition>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% RTA 408 opthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% RTA 408 ophthalmic suspension, one drop applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% RTA 408 opthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% RTA 408 ophthalmic suspension, one drop applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Opthalmic suspension manufactured to mimic RTA 408 suspension</description>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% RTA 408 Ophthalmic Suspension</intervention_name>
    <description>0.5% ophthalmic suspension of RTA 408</description>
    <arm_group_label>0.5% RTA 408 opthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% RTA 408 Ophthalmic Suspension</intervention_name>
    <description>1% ophthalmic suspension of RTA 408</description>
    <arm_group_label>1% RTA 408 opthalmic suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be male or female and ≥18 years of age and ≤80 years of age

          2. Plan to undergo cataract extraction by phacoemulsification with the implantation of a
             posterior chamber intraocular lens

          3. Have the potential, in the opinion of the investigator, to improve best-corrected
             visual acuity in the study eye after surgery

          4. Have Grade 3, 4, or 5 nuclear cataract in the study eye, according to the LOCS III

          5. Have corneal endothelium in the study eye that can be accurately assessed using
             specular microscopy

          6. Have endothelial cell density of &gt;1800 cells/mm2 in the study eye at the Screening
             Visit

          7. Have a pinhole visual acuity (VA) of at least 1.0 logarithm of the minimum angle of
             resolution (logMAR) in the study eye and fellow eye as measured using an Early
             Treatment for Diabetic Retinopathy Study (ETDRS) chart

        Exclusion Criteria:

          1. Have a score &gt;0 on the ocular pain assessment at the Screening Visit or the
             Randomization Visit in the study eye

          2. Have an active immunosuppressive disease or an autoimmune disease that, in the
             opinion of the investigator, could affect the quality of the ocular surface

          3. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and
             will likely affect wound healing

          4. Have an intraocular pressure (IOP) ≤5 mmHg in either eye

          5. Have had corneal or retinal surgery (laser or incisional) within the past 6 months,
             or be planning to have laser or incisional surgery during the study period in the
             study eye

          6. Have the presence of guttae Stage 2 or greater or other abnormality in the study eye
             that does not allow for accurate corneal endothelial cell assessments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Argus Research</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>239-542-2020</phone>
    </contact>
    <investigator>
      <last_name>Farrell Tyson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>904-366-3781</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Levenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>847-748-3553</phone>
    </contact>
    <investigator>
      <last_name>Parag Majmudar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>816-350-4539</phone>
    </contact>
    <investigator>
      <last_name>John Doane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Opthalmic Consultants of Boston</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-504-9334</phone>
    </contact>
    <investigator>
      <last_name>Bonnie Henderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Vision Center</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>952-835-1235</phone>
    </contact>
    <investigator>
      <last_name>Ralph Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>636-390-3999</phone>
    </contact>
    <investigator>
      <last_name>Michael Korenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi and Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>845-454-1025</phone>
    </contact>
    <investigator>
      <last_name>Satish Modi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>513-569-3462</phone>
    </contact>
    <investigator>
      <last_name>Michael Snyder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R &amp; R Eye Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>210-340-1212</phone>
    </contact>
    <investigator>
      <last_name>Charles Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>Cataract surgery</keyword>
  <keyword>Corneal Endothelial Cells</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Eye Pain</mesh_term>
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
